Huntington's disease: Underlying molecular mechanisms and emerging concepts

Trends in Biochemical Sciences

Volumn 38, Issue 8, 2013, Pages 378-385

  Labbadia, John ^a   Morimoto, Richard I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Huntington's disease; Molecular mechanisms; Therapeutic approaches

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTISENSE OLIGONUCLEOTIDE; DYNAMIN I; HEAT SHOCK PROTEIN 70; HEAT SHOCK TRANSCRIPTION FACTOR 1; HSF1 ACTIVATOR; HUNTINGTIN; KYNURENIC ACID; KYNURENINE 3 MONOOXYGENASE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXYGENASE INHIBITOR; PLATINUM DICHLOROBIS(ISOPROPYLAMINE); POLYGLUTAMINE; PROTEIN DNAJ; QUINOLINIC ACID; SIRTUIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CAG REPEAT; COGNITIVE DEFECT; DRUG TARGETING; EXCITOTOXICITY; GENE; GENE MUTATION; HTT GENE; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; LOW DRUG DOSE; NERVE CELL NETWORK; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; REVIEW; RNA INTERFERENCE; SPINOCEREBELLAR DEGENERATION;

HUNTINGTON'S DISEASE; MOLECULAR MECHANISMS; THERAPEUTIC APPROACHES;

ANIMALS; BRAIN; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MUTATION; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PROTEIN STABILITY; UNFOLDED PROTEIN RESPONSE;

EID: 84880730823     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2013.05.003     Document Type: Review

References (85)

1. Munoz-Sanjuan I., Bates G.P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J. Clin. Invest. 2011, 121:476-483.
2. Warby S.C., et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur. J. Hum. Genet. 2011, 19:561-566.
3. Williams A.J., Paulson H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008, 31:521-528.
4. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
5. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
6. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:49-60.
7. Miller J., et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 2011, 7:925-934.
8. Jeong H., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
9. Gu X., et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009, 64:828-840.
10. Tam S., et al. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat. Struct. Mol. Biol. 2009, 16:1279-1285.
11. Thakur A.K., et al. Polyglutamine disruption of the huntingtin exon 1N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 2009, 16:380-389.
12. Kar K., et al. Critical nucleus size for disease-related polyglutamine aggregation is repeat-length dependent. Nat. Struct. Mol. Biol. 2011, 18:328-336.
13. Ren P.H., et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 2009, 11:219-225.
14. Shirasaki D.I., et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 2012, 75:41-57.
15. Ehrnhoefer D.E., et al. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat. Rev. Drug Discov. 2011, 10:853-867.
16. Eidelberg D., Surmeier D.J. Brain networks in Huntington disease. J. Clin. Invest. 2011, 121:484-492.
17. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-523.
18. Li H., et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 2001, 21:8473-8481.
19. Morfini G.A., et al. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat. Neurosci. 2009, 12:864-871.
20. Okamoto S., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
21. Subramaniam S., et al. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
22. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.
23. Zwilling D., et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145:863-874.
24. Campesan S., et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 2011, 21:961-966.
25. van der Goot A.T., et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:14912-14917.
26. Prahlad V., et al. Regulation of the cellular heat shock response in Caenorhabditis elegans by thermosensory neurons. Science 2008, 320:811-814.
27. Prahlad V., Morimoto R.I. Neuronal circuitry regulates the response of Caenorhabditis elegans to misfolded proteins. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14204-14209.
28. Garcia S.M., et al. Neuronal signaling modulates protein homeostasis in Caenorhabditis elegans post-synaptic muscle cells. Genes Dev. 2007, 21:3006-3016.
29. Cicchetti F., et al. Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 2011, 134:641-652.
30. Mochel F., Haller R.G. Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 2011, 121:493-499.
31. Orr A.L., et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 2008, 28:2783-2792.
32. Weydt P., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
33. Cui L., et al. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
34. Costa V., Scorrano L. Shaping the role of mitochondria in the pathogenesis of Huntington's disease. EMBO J. 2012, 31:1853-1864.
35. Song W., et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 2011, 17:377-382.
36. Li Q., et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21146-21151.
37. Rugarli E.I., Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 2012, 31:1336-1349.
38. Seredenina T., Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease?. Neurobiol. Dis. 2012, 45:83-98.
39. Dunah A.W., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
40. Schaffar G., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 2004, 15:95-105.
41. Zhai W., et al. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005, 123:1241-1253.
42. Huang S., et al. Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor. Brain 2011, 134:1943-1958.
43. Yamanaka T., et al. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J. 2008, 27:827-839.
44. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
45. Chuang D.M., et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32:591-601.
46. Bates E.A., et al. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 2006, 26:2830-2838.
47. Pallos J., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
48. Balch W.E., et al. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
49. Gidalevitz T., et al. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006, 311:1471-1474.
50. Gupta R., et al. Firefly luciferase mutants as sensors of proteome stress. Nat. Methods 2011, 8:879-884.
51. Hay D.G., et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 2004, 13:1389-1405.
52. Gidalevitz T., et al. Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. PLoS Genet. 2009, 5:e1000399.
53. Olzscha H., et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 2011, 144:67-78.
54. Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6:11-22.
55. Hageman J., et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol. Cell 2010, 37:355-369.
56. Labbadia J., et al. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 2012, 135:1180-1196.
57. van Ham T.J., et al. Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity. Cell 2010, 142:601-612.
58. Li X.J., Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 2011, 43:4-8.
59. Bennett E.J., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
60. Hipp M.S., et al. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J. Cell Biol. 2012, 196:573-587.
61. Martinez-Vicente M., et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat. Neurosci. 2010, 13:567-576.
62. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13:805-811.
63. Chafekar S.M., Duennwald M.L. Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS ONE 2012, 7:e37929.
64. Labbadia J., et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 2011, 121:3306-3319.
65. Riva L., et al. Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1. J. Huntington's Dis. 2012, 1:33-45.
66. Jiang M., et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med. 2012, 18:153-158.
67. Jeong H., et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 2012, 18:159-165.
68. Westerheide S.D., et al. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009, 323:1063-1066.
69. Sadagurski M., et al. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J. Clin. Invest. 2011, 121:4070-4081.
70. Cohen E., et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139:1157-1169.
71. Neef D.W., et al. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat. Rev. Drug Discov. 2011, 10:930-944.
72. Neef D.W., et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010, 8:e1000291.
73. Calamini B., et al. Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol. 2012, 8:185-196.
74. Landles C., et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 2010, 285:8808-8823.
75. Graham R.K., et al. Caspase-6 and neurodegeneration. Trends Neurosci. 2011, 34:646-656.
76. Tebbenkamp A.T., et al. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum. Mol. Genet. 2011, 20:2770-2782.
77. Miller J.P., et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 2010, 67:199-212.
78. Sathasivam K., et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2366-2370.
79. Yamamoto A., et al. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
80. Yu D., et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012, 150:895-908.
81. Kordasiewicz H.B., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044.
82. Liu C.R., et al. Spt4 is selectively required for transcription of extended trinucleotide repeats. Cell 2012, 148:690-701.
83. Raymond L.A., et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
84. Powers E.T., et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 2009, 78:959-991.
85. Davidson B.L., Monteys A.M. Singles engage the RNA interference pathway. Cell 2012, 150:873-875.